Regdanvimab

瑞达韦单抗

Report date: 2022/11/25 14:59:41

Base Information

Drug NameRegdanvimab
Drug Alias NameCT-P59丹维单抗RegkironaCT-P59
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2021/09/18
Country/TerritorySouth KoreaEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Inc
Inactive CompaniesCelltrion Healthcare Hungary Kft
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A